Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MEDS boomage
MEDS beasting
$MEDS many eyes on this one
$GGAA 400K FLOAT
$FERN - bitcoin play looks ready
FERN therrrrrrrrr she goes
FERN - bitcoin play not front run
bitcoin up big >>>>>>. FERN just starting.
bitcoin 30k, FERN moving now.
L2 showing to be bullish !!!!
$MULN yes MULN
agreed .003 key level
PWDY strong
$PWDY
leas SOOOO THIN
[b$LEAS ready]
$LEAS ready
$ LEAS , yes does look like no brainer, we shall see.
$LEAS also :)
$LEAS HOD
$LEAS .002S up
$WETG strong post split, a lil more volume and a halt is possible IMO.
$WETG
$WETG post split
AHI to 5?
$LEAS NO BRAINER
$LEAS filled , with that filing ,its a no brainer here .dang.
$CYXT early and often.
$CYXT going .066
$FRZA
looks like a positive PB
$CNTB nice news from last night Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:05 pm ET June 1, 2023 (Globe Newswire) Print
GlobeNewswireJune 01, 2023
Icanbelimod demonstrated sustained clinical remission, a regulatory relevant efficacy endpoint, through Week 48 in 80% of patients who achieved clinical remission at Week 12 of the induction period.
Icanbelimod continued to be well-tolerated, consistent with observed induction period safety data.
SAN DIEGO, CA and TAICANG, China, June 01, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced positive data at Week 48 from Phase 2 trial (CN002) for icanbelimod (formerly known as CBP-307), a once-daily, orally administered, selective sphingosine 1-phosphate receptor 1 (S1P1) modulator in development for the treatment of ulcerative colitis (UC).
MEOA shareholder meeting tom at 2 EST
Indeed
MEOA halted up name change commith
$ARVL gonzo
$ARVL oh def Augusta
$CELZ another pr today. Creative Medical Technology Holdings Announces Next Milestone Achievements In ImmCelz Platform Development; Advancements May Result In Ability To Treat A Broader Patient Population With Immune Disorders
8:43 am ET May 22, 2023 (Benzinga) Print
Advancements May Result in Ability to Treat a Broader Patient Population with Immune Disorders
PHOENIX, May 22, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced significant advances in the ongoing development of its ImmCelz® (CELZ-100) platform, the Company's cell-free system which has previously been validated to supercharge a patient's own cells to treat a number of immune disorders.
$ARVL DE -SPAC
ARVL Loooook ARRIVAL Reports Q1 2023 Business Update; Ending Cash Position Of $130M; Business Combination Agreement With Kensington Capital Acquisition Corp. V To Provide Additional Manufacturing Expertise And Up To $283 Million From Cash In Trust
12:22 am ET May 16, 2023 (Benzinga) Print
Business Combination Agreement with Kensington Capital Acquisition Corp. V to Provide Additional Manufacturing Expertise and Up to $283 Million From Cash in Trust
First Quarter Ending Cash Position of $130 Million
LUXEMBOURG, May 15, 2023 (GLOBE NEWSWIRE) -- Arrival (NASDAQ:ARVL) ("Arrival" or the "Company"), inventor of a unique new method of design and production of electric vehicles, today provided business updates for the first quarter ended March 31, 2023.